Reunion Neuroscience (TSX:REUN) Buildings And Improvements : C$0.00 Mil (As of Mar. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience Buildings And Improvements?

Reunion Neuroscience Buildings And Improvements Historical Data

The historical data trend for Reunion Neuroscience's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience Buildings And Improvements Chart

Reunion Neuroscience Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Buildings And Improvements

Reunion Neuroscience Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Buildings And Improvements	Get a 7-Day Free Trial										-	-	-	-	-

Reunion Neuroscience Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Reunion Neuroscience (TSX:REUN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3

Website

https://www.reunionneuro.com

Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.